0000000000523517

AUTHOR

Wolf-k. Hofmann

showing 3 related works from this author

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therap…

2002

In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2). Fifty-five patients (41 male, 14 female) with a median age of 34 yea…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentHematopoietic growth factormedicine.medical_treatmentOpportunistic InfectionsNeutropeniaGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansProspective StudiesChemotherapyMitoxantroneHematologybusiness.industryCytarabineHematologyGeneral MedicineMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHematopoiesisSurgeryGranulocyte colony-stimulating factorLenograstimTreatment OutcomeFemalebusinessmedicine.drugAnnals of Hematology
researchProduct

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

2015

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n=40). The rate of molecular (m)CR was 74% in hematological and 62% in molecular relapse (P=0.3). All patients with extramedullary relapse (n=11) entered clinical and mCR. After 3.2 years median follow-u…

MaleCancer ResearchInternational CooperationGastroenterologyArsenicalsEuropean LeukemiaNetchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteRecurrence80 and overCumulative incidenceProspective StudiesRegistriesLeukocytosisArsenic trioxideChildAged 80 and overPromyelocyticLeukemiaCell DifferentiationOxidesHematologyMiddle AgedEuropeLeukemiaTreatment OutcomeOncologyChild PreschoolFemalemedicine.symptomAdultAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentAntineoplastic AgentsAcuteDisease-Free SurvivalYoung AdultInternal medicinemedicineHumansAutologous transplantationPreschoolAgedbusiness.industrymedicine.diseaseSurgeryTransplantationAdolescent; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Arsenicals; Cell Differentiation; Child; Child Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia Promyelocytic Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young AdultchemistrybusinessSettore MED/15 - Malattie del SangueLeukemia
researchProduct

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and h…

2000

Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged/=60 years and 35% aged60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high-…

AdultMalemedicine.medical_specialtyAdolescentGastroenterologyInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineIdarubicinProspective StudiesSurvival rateEtoposideAgedEtoposideDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesCytarabineHematologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateLeukemiaLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseCytarabineInterleukin-2FemaleImmunotherapyIdarubicinbusinessRefractory anemia with excess of blastsmedicine.drugAnnals of Hematology
researchProduct